Welcome to our dedicated page for Nektar Therapeutics SEC filings (Ticker: NKTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nektar Therapeutics (NKTR) SEC filings page brings together the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Nektar’s common stock is registered under Section 12(b) of the Exchange Act and trades on the Nasdaq Capital Market, and its filings provide structured insight into clinical progress, capital markets activity and corporate governance.
Recent Form 8-K reports include detailed descriptions of topline results from the Phase 2b REZOLVE-AD trial in atopic dermatitis and the Phase 2b REZOLVE-AA trial in alopecia areata, including study design, patient populations, primary and secondary endpoints, and summarized efficacy and safety outcomes. Other 8-K filings cover financial results for completed quarters, underwritten equity offerings under an effective shelf registration statement, and notices related to Nasdaq minimum bid price compliance.
Through these filings, investors can review how Nektar characterizes rezpegaldesleukin (REZPEG, or NKTR-358) as a first-in-class regulatory T cell stimulator and IL-2 pathway agonist, and how it describes additional pipeline programs such as NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255. Filings also outline FDA Fast Track designations for rezpegaldesleukin in atopic dermatitis and alopecia areata, as well as risk factor language and forward-looking statement disclaimers that frame development and regulatory uncertainty.
On Stock Titan, these SEC documents are updated as they are made available on EDGAR. AI-powered tools can help explain key sections of Nektar’s 8-Ks and related reports in plain language, highlight important clinical and financing disclosures, and surface items such as listing status updates and material agreements. This allows readers to quickly understand the implications of new filings for Nektar’s immunology pipeline and its Nasdaq-listed equity.
Diana Brainard, a director of Nektar Therapeutics (NKTR), was granted an option for 8,000 shares on 09/30/2025. The option has an exercise price of $56.90 and is recorded as a direct holding of 8,000 underlying shares following the transaction. The option vests in substantially equal monthly installments over the one-year period beginning on September 30, 2025, and the instrument shows an exercisable/expiration date of 09/29/2033. The Form 4 is signed by an attorney-in-fact on 10/01/2025, reporting the acquisition (code A) of the derivative security.
Jeffrey Robert Ajer, a director of Nektar Therapeutics (NKTR), acquired a derivative grant of 8,000 stock options on 09/30/2025. The options have a stated conversion/exercise price of $56.9 and the filing reports 8,000 underlying shares of common stock. The filing notes the options vest in substantially equal monthly installments over the one-year period beginning on September 30, 2025. The form indicates an expiration/related date of 09/29/2033 and shows the shares are beneficially owned directly following the transaction. The Form 4 was signed by an attorney-in-fact on 10/01/2025.
Nektar Therapeutics filed a current report describing new clinical data from its ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin in atopic dermatitis. The company posted a slide deck on its website with additional efficacy and safety information and furnished it as Exhibit 99.1. Nektar also issued a press release about the new data and a late-breaker oral presentation at EADV 2025, furnished as Exhibit 99.2. These materials are being furnished, not filed, which limits their use under certain securities law provisions.
Nektar Therapeutics filed a current report describing new clinical data from its ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin in atopic dermatitis. The company posted a slide deck on its website with additional efficacy and safety information and furnished it as Exhibit 99.1. Nektar also issued a press release about the new data and a late-breaker oral presentation at EADV 2025, furnished as Exhibit 99.2. These materials are being furnished, not filed, which limits their use under certain securities law provisions.
Insider sales by Nektar Therapeutics CEO and Director Robin W. Howard are reported on Form 4. On 09/09/2025 Mr. Howard sold a series of common stock lots under a disclosed Rule 10b5-1 trading plan: 2,100 shares at a weighted average price of $45.16, 1,200 shares at $46.41, 2,156 shares at $47.49, and 1,210 shares at $48.18. The filings show his beneficial ownership declined through the sequence from 53,908 shares to 49,342 shares after the last reported sale; an indirect holding of 28 shares is listed as held by his spouse. The report was executed under an established trading plan and the filer states willingness to provide trade-level details on request.
Form 144 filed for NKTR (Nektar Therapeutics) reports a proposed sale of 6,666 common shares by an insider through Fidelity Brokerage Services on 09/09/2025 on NASDAQ, with an aggregate market value of $311,204.76. The filing lists total shares outstanding as 19,018,573. The shares to be sold match the sum of restricted stock vesting awards acquired between 05/15/2016 and 11/15/2021 that total 6,666 shares and were granted as compensation. The seller is identified as Howard Robin at the provided address. Recent dispositions by the same person in the prior three months total 14,905 shares for gross proceeds of $518,026.81 across four sales dated 08/19/2025 through 09/05/2025. The filing does not include the issuer name, CIK, or certain contact details in the provided text.
Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics (NKTR), reported four sales of company common stock on 09/04/2025 under a Rule 10b5-1 trading plan. The transactions disposed of 1,721 shares in total (793; 432; 189; 307) at weighted average prices of $32.43, $33.60, $34.41, and $35.69 respectively, with execution price ranges disclosed for each lot. Following these sales, the reporting person beneficially owned 17,462 shares (direct ownership). The filing indicates the trades were executed pursuant to a pre-established plan and the filer offers to provide full trade-by-trade details on request.
Robin W. Howard, President & CEO and director of Nektar Therapeutics (NKTR), sold a total of 11,832 shares of common stock under a Rule 10b5-1 trading plan on September 4-5, 2025. The sales were reported in several block transactions with weighted-average prices reported at $32.37, $33.54, $34.40, $35.80, $37.87, $38.82 and $39.89. Following these dispositions the reporting person beneficially owned 56,008 shares directly; an additional 28 shares are held indirectly by the reporting person’s spouse. The filer states the transactions were effected pursuant to a 10b5-1 plan and provides price ranges for each grouped trade.
Nektar Therapeutics (NKTR) notice reports a proposed sale of 6,666 common shares with an aggregate market value of $256,837.92, representing a portion of ~19.02 million shares outstanding. The filing identifies the broker as Fidelity Brokerage Services LLC and lists the approximate date of sale as 09/05/2025 on NASDAQ. The 6,666 shares to be sold were acquired through restricted stock vesting between 05/15/2017 and 05/15/2021 as compensation from the issuer, and the acquisition table shows the same 6,666-share total when summed. The filer also disclosed three sales in the prior three months totaling 8,239 shares for gross proceeds of $261,188.89. The notice includes the seller's attestation regarding absence of undisclosed material adverse information.
Nektar Therapeutics (NKTR) insider sale disclosed on Form 4. Jonathan Zalevsky, Chief R&D Officer, reported selling 485 shares of common stock on 09/02/2025 under a Rule 10b5-1 trading plan at a weighted average price of $30.10 per share. After the sale he beneficially owned 19,183 shares, held directly. The filing states the trades executed at prices ranging from $30.00 to $30.28 and the Form 4 was signed by an attorney-in-fact on 09/04/2025.
Robin W. Howard, President & CEO and director of Nektar Therapeutics (NKTR), reported an insider sale on 09/02/2025. The filing shows a disposition of 1,500 shares of common stock executed at a weighted-average price of $30.16, reducing his direct beneficial ownership to 67,840 shares. The report notes the sale was made pursuant to a Rule 10b5-1 trading plan and that the trades occurred at prices between $30.00 and $30.30. The form also discloses an indirect ownership of 28 shares held by his spouse. The filing was signed by an attorney-in-fact on 09/04/2025.